The FDA granted accelerated approval to olaratumab (Lartruvo, Eli Lilly) with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate, and which is not amenable to curative treatment with radiation therapy or surgery.
Olaratumab’s indication is based on data from the Phase II portion of the pivotal JGDG trial. Continued approval for this indication may be contingent